Skip to main content

Table 1 The anti-cancer effect of cGAS-STING agonist

From: Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

cGAS-STING agonist

Cancer type

Agent delivery

Ref.

3′3′-cGAMP

Mouse B cell malignancies

Intraperitoneal injection

[109]

2′3′-cGAMP

Mouse lymphoma

Intratumoral injection

[63]

ML RR-S2 CDG

Mouse melanoma

Intratumoral injection

[69]

ML RR-S2 cGAMP

Mouse melanoma

Intratumoral injection

[69]

ML RR-S2 CDA (ADU-S100)

Mouse melanoma, colon cancer, mammary carcinoma

Intratumoral injection

[61, 69, 70]

DMXAA†

Mouse lung cancer, mesothelioma, human lung cancer, and prostate cancer

Intravenous injection

[110,111,112]

Cyclic di-GMP

Mouse melanoma, prostate cancer, glioma, breast cancer

Intratumoral injection

[22, 94, 113, 114]

DiABZI

Mouse colon tumor

Intravenous injection

[72]

  1. Agent delivery listed in the table is the common delivery approach of cGAS-STING agonist. Cyclic dinucleotide encapsulated by some nanoparticles such as endosomolytic polymersomes could be delivered by intravenous injection as well [71]
  2. cGAMP cyclic GMP-AMP, CDA cyclic di-AMP, ML mixed linkage, DMXAA 5,6-dimethylxanthenone-4-acetic acid, DiABZI dimeric amidobenzimidazole, CDG cyclic di-GMP
  3. †Mouse STING-specific agonist with weak binding affinity to human STING, failing to pass phase III clinical trials